GeneScience Pharmaceuticals Co., Ltd.
GeneScience Pharmaceuticals Co., Ltd., commonly referred to as GeneScience, is a leading biopharmaceutical company headquartered in China (CN). Established in 2002, the company has made significant strides in the biotechnology sector, focusing on the research, development, and production of innovative biopharmaceuticals. With a strong presence in both domestic and international markets, GeneScience excels in areas such as recombinant proteins, monoclonal antibodies, and biosimilars. Their flagship products, including the well-regarded EPO and G-CSF, are distinguished by their high quality and efficacy, setting them apart in a competitive landscape. Recognised for its commitment to advancing healthcare, GeneScience has achieved notable milestones, including numerous regulatory approvals and partnerships that enhance its market position. As a pioneer in the biopharmaceutical industry, GeneScience continues to drive innovation and improve patient outcomes globally.
DitchCarbon Score
How does GeneScience Pharmaceuticals Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GeneScience Pharmaceuticals Co., Ltd.'s score of 24 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GeneScience Pharmaceuticals Co., Ltd.'s reported carbon emissions
In 2022, GeneScience Pharmaceuticals Co., Ltd. reported total carbon emissions of approximately 11,853,000 kg CO2e, comprising 328,000 kg CO2e from Scope 1 emissions and 11,525,000 kg CO2e from Scope 2 emissions. This represents a decrease from 2021, when the company emitted about 10,819,000 kg CO2e, with Scope 1 emissions at 485,000 kg CO2e and Scope 2 emissions at 10,334,000 kg CO2e. Despite these reductions, GeneScience has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company has focused on transparency in its emissions reporting, covering both Scope 1 and Scope 2 emissions, while not providing data on Scope 3 emissions. As a pharmaceutical company headquartered in China, GeneScience is part of an industry increasingly scrutinised for its environmental impact, highlighting the importance of robust climate commitments and emissions reduction strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 485,000 | 000,000 |
| Scope 2 | 10,334,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GeneScience Pharmaceuticals Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
